Mice were very much on the minds of guests staying at the Hilton Tokyo Bay from 14 to 16 November 2011. Th e hotel is a short distance from Tokyo Disneyland and, for most guests, the mice were of the cartoon variety that descended from Steamboat Willie. Now known as Mickey Mouse, Steamboat Willie was the brilliant product of Walt Disney's imagination. Not surprisingly, more than a few children cavorting in the hotel lobby wore the iconic black ears as treasured souvenirs of their trip to the Magic Kingdom.
Th e other Hilton guests thinking about mice were attending the BRIC-GARN Meeting 2011. Th is outstanding international congress, organized by Professor Kusuki Nishioka, Director and Chairman, Institute of Medical Science, Tokyo, encompassed both the Bio-Rheumatology International Congress (BRIC) and the ninth Global Arthritis Research Network (GARN) meeting. Th e GARN meeting brings together investigators from around the world to discuss the pathogenesis and treatment of infl ammatory arthritis. For these people, the mice uppermost in the mind were of the knockout and transgenic kind. Indeed, one of the highlights of the meeting was a presentation on slickly engineered rodents whose cells glowed neon-bright to track the peregrinations of an overexpressed fl uorescent protein construct.
Among tissues featured at the meeting, bone received signifi cant attention -especially with regard to the interface with the immune system. Indeed, bone -often viewed as an inert, albeit durable and hard, scaff old for the body construction -is intensively dynamic as osteoclasts and osteoblasts engage in relentless surface remodel ing. In this lively cellular pas de deux, RANK-RANKL interactions are at the center of action. As therapies targeting RANKL enter practice, questions will abound on the conse quences of its inhibition, not only for the bone itself but for the immune cells that also utilize this system. Indeed, as described by Professor Yongwon Choi from University of Pennsylvania in his study on a molecule called OSCAR, osteoclasts and osteoclasts have many similari ties to T cells and antigen-presenting cells; bone cells are homebodies, however, whereas immune cells are wanderers.
Another cell in the spotlight at the meeting was the fi broblast. As shown in studies by Professor Steff en Gay from Zurich, synovial fi broblasts play a key role in the pathogenesis of rheumatoid arthritis (RA), with an invasive and destructive phenotype bearing the hallmark of epigenetic modifi cation. Th e driving force of such modifi cation is not known but the presence of aberrant base methylation suggests that pathogenesis involves changes to the DNA at the cellular level. As such, agents that undo epigenetic modifi cation could have therapeutic benefi t by reconfi guring genes and returning the fi broblasts to a more subdued and tractable state. Intriguingly, one compound that has potential as an epigenetic modifi er is S-adenosyl methionine. Called SAME (pronounced Sammy), this agent has long had popularity as an alternative therapy for RA and was touted on American television by the actor James Coburn of Our Man Flint fame. Coburn himself had severe RA. Imagine the irony if SAME turned out to be the real deal.
Professor Gay also highlighted the importance of miRNA in the regulation of fi broblast biology. miRNA is hot right now and the role of these regulatory nucleic acids was reprised in presentations by Professor Iain McInnnes from Glasgow and Professor Nan Shen from Shanghai. Many studies in the future will no doubt investigate miRNA signatures as biomarkers comparable with mRNA signatures. Th e potential of miRNAs as targets of therapy remains to be tested, however, with such approaches possibly encountering the same obstacles as did antisense; the delivery of nucleic acids inside cells can be a challenge to say the least. Th us far, synovial fi broblasts have not been put directly in the cross-hairs of a targeted therapy, although undoubtedly many current agents can aff ect the function of these cells by reducing the activity of other interacting cell types and their production of mediators.
A study by Professor Ulf Muller-Ladner from Giessen raised the intriguing possibility that synovial fi broblasts can migrate from joint to joint, in essence causing synovitis to metastasize. Th ese experiments were performed in a SCID mouse model in which synovial tissue and cartilage from a patient are implanted into the mouse and cell migration is tracked by immuno fl uores cence. Interestingly, in this model, cartilage damage may be necessary to provide a stopping place for fi broblasts on the lookout for a new place to wreak havoc. Th us, while the implanted human cartilage suff ered the attack of the fi broblasts, the joints of the mouse remain un perturbed. Such observations could suggest that, while RA has a strong component of autoimmunity, tissue injury may be critical to initiate the process.
As studies of new models show, mice can provide exceptionally powerful systems for detailed molecular dissection and can suggest novel mechanisms by which synovial infl ammation can arise. While mouse models will remain a mainstay of investigation in rheumatology, there is nevertheless uncertainty about their value to predict treatment responses in man. Th e road for any new product to the clinic will inevitably pass through the cages of inbred mice, but demonstration of the effi cacy of a new therapy for RA or systemic lupus erythematosus in mice is no guarantee of success in man. As described by Professor Peter Lipsky (Charlottesville), the success of Bcell-directed therapy in mouse models of lupus has yet to be replicated in man. While trial design issues may hamper drug testing in patients, human and murine lupus may be suffi ciently diff erent to preclude a smooth and easy translation. Given the current costs of developing a new agent, such uncertainty can be chilling to companies, investigators and investors.
Together, studies of both murine and human disease have produced an abundance of data to construct models for pathogenesis. Th ese models can be represented schemati cally as branched networks like a circuit diagram, although they grow ever more complex with multiple arrows connecting cell types, on the one hand, and signal ing pathways, on the other. Such schematic representations, while informative, are inherently limited b ecause of their two-dimensional nature. At least four dimensions, including time, will be required for modeling a complex disease like arthritis. Furthermore, in disease pathogenesis there are many unknown unknownsincluding mediators driving synovitis that are yet to be identifi ed. Th us, as described by Professor McInnes, synovial fl uid con tains a component that can drive synovial fi broblasts. While this component has potent activity, its identity is a mystery. In addition to diffi culties with unknown players, the schematic representations do not put value signs on the interactions. No doubt some arrows are thin and some are thick, but we do not know which is which.
Th e role of the nervous system must also be considered in understanding the pathogenesis of RA as well as the response to treatment. RA is an inherently painful condition and, as shown elegantly by Professor Georg Schett from Erlangen, TNF can be a powerful mediator of pain. Indeed, some of the dramatic and almost immediate treatment responses of TNF blockers may result from their profound analgesic eff ects and the modulation of central pain pathways. Such eff ects may not occur with other biological or targeted therapies that, while eff ective, may not produce the same clash of the therapeutic cymbal that excites hopes of a revolutionary advance. Professor Nishioka also discussed pain from the perspective of fi bromyalgia and the development of new measures to characterize this important condition, which can occur alone or as a consequence of diseases such as RA and systemic lupus erythematosus.
In this setting, the presentation of the Masterswitch initiative by Professor Tom Huizinga of Lieden provided the basis for lively discussion. Masterswitch is a program of the European Union that involves sites around the continent to identify key points in the pathogenesis of infl ammatory arthritis that are putatively switched on during disease and, hopefully, can be switched off during therapy. Professor Huizinga described the expression of IgE antibodies to citrullinated proteins as one such possible switch event. While the role of the basophil in RA pathogenesis has long been suspected, the presence of IgE antibodies to citrullinated proteins provides a neat way to trigger these cells to dump their contents into the witch's brew that boils in the rheumatoid joint.
How many switches will there be and will any have mastery over the others? My take on the literature is that RA is a process that can be switched on and switched off in many diff erent ways. Indeed, consideration of the properties of existing disease-modifying anti-rheumatic drugs fails to reveal any common or unifying action, beyond restraining overall immune activity. In this case, a rheostat may be a better analogy than a switch. Fortunately, current therapy can produce impressive results, with evidence that at least some patients treated with biological agents can have therapy withdrawn and still show disease control. Perhaps a withdrawal phase should be part of clinical trials in the future. For reasons of costs and safety, we need to know whether continued treatment with biological agents is necessary once remission is obtained and to develop ways to identify when disease is truly quiescent.
For those not old enough to remember the excitement, awe and even frenzy that the idea of Disneyland engendered, the original television program and park featured four diff erent lands -Fantasyland, Frontierland, Tomorrowland, and Adventureland. In the same way, a good science meeting like BRIC-GARN inhabits diff erent lands and the terminology would not be too diff erent since scientists like to think about the future, have adventures, and forge new frontiers. Fantasy can also be a healthy part of science. While I do not think there was too much fantasy at the Tokyo meeting, many people nevertheless thought treating RA with a monoclonal anti-cytokine antibody, as described by Professor Tiny Maini from London, was worthy of a place just next to the Mad Tea Party and Pinocchio's Daring Journey. Like the others who were fortunate to attend this meeting, I had a wonderful time near the Magic Kingdom and await with great interest the opportunity to explore the new lands of arthritis research and therapy.
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